Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





FlashDx Launches New Respiratory and MRSA/SA Panels at MEDICA 2025

By LabMedica International staff writers
Posted on 17 Nov 2025

FlashDx is introducing two new molecular diagnostic assays at MEDICA 2025—the Respiratory Panel 2 and the MRSA/SA Panel. More...

The launch of these assays further extends FlashDx’s multiplex molecular testing portfolio, reinforcing the company’s commitment to advancing near-patient molecular diagnostics through innovation and automation. FlashDx will also demonstrate its fully automated multiplex molecular diagnostic system, powered by its proprietary sSPRT (semi-Solid Phase Real-Time PCR) technology.

The company is debuting Respiratory Panel 2, which targets additional respiratory pathogens to complement the existing Respiratory Panel 1.1. By broadening organism coverage, the new panel is intended to increase diagnostic flexibility while maintaining a syndromic testing approach. FlashDx is also launching an MRSA/SA Panel for rapid and precise detection of Methicillin resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA), addressing routine screening and infection control needs in hospitals and clinics.

FlashDx is demonstrating its sSPRT powered platform at MEDICA 2025. The sSPRT platform enables rapid, accurate, and multiplex pathogen detection within a fully integrated “sample-to-result” workflow, designed to meet the growing needs of infectious disease and reproductive health diagnostics. Built to comply with the EU’s stringent IVD Regulation standards, the system maintains full regulatory integrity without sacrificing speed or flexibility. Its expandable, multi-slot instrumentation provides true random access to a wide range of disease panels and sample types—anytime and anywhere—allowing laboratories to scale testing confidently while meeting global quality and safety requirements

Attendees can meet FlashDx in Hall 3, Booth H26 at MEDICA 2025 to review the new assays and discuss opportunities for collaboration. Founded by U.S. and European industry experts with Silicon Valley know-how, FlashDx offers a turnkey, sample-to-answer platform and a portfolio of syndromic infectious disease cartridges, with plans to expand into oncology and other disease areas.

Related Links:
FlashDx

 


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.